On the other hand, in cancer cells, NRF2 tends to be overexpressed as a result of either constitutive activation or hyperactivation, allowing them to survive in ROS-rich environments (known as redox adaptation), which comes hand in hand with their increased proliferation and increased resistance to chemotherapy, which, a lot of the time, depends on ROS generation. Here, NFE2L2 is linked to cancer.